Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Operating Expenses (2017 - 2025)

Crinetics Pharmaceuticals has reported Operating Expenses over the past 9 years, most recently at $139.8 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 47.58% year-over-year to $139.8 million; the TTM value through Dec 2025 reached $524.5 million, up 54.3%, while the annual FY2025 figure was $524.5 million, 54.3% up from the prior year.
  • Operating Expenses for Q4 2025 was $139.8 million at Crinetics Pharmaceuticals, down from $142.7 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $142.7 million in Q3 2025 and troughed at $22.9 million in Q1 2021.
  • A 5-year average of $68.6 million and a median of $56.7 million in 2023 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 66.68% in 2022 and later increased 24.14% in 2023.
  • Year by year, Operating Expenses stood at $32.0 million in 2021, then skyrocketed by 50.99% to $48.3 million in 2022, then rose by 29.82% to $62.7 million in 2023, then skyrocketed by 51.21% to $94.7 million in 2024, then surged by 47.58% to $139.8 million in 2025.
  • Business Quant data shows Operating Expenses for CRNX at $139.8 million in Q4 2025, $142.7 million in Q3 2025, and $130.1 million in Q2 2025.